The role of targeted agents in adjuvant therapy for non-small cell lung cancer

Area of Science:

• Oncology
• Translational Medicine
• Clinical Trial Design

Background:

• Recent adjuvant chemotherapy demonstrated survival benefits in early-stage non-small cell lung cancer (NSCLC).
• This success offers optimism for the potential of targeted therapies in the adjuvant setting for NSCLC.
• However, integrating targeted agents into adjuvant treatment strategies presents challenges.

Purpose of the Study:

• To address the challenge of incorporating molecularly targeted agents into the adjuvant treatment of early-stage non-small cell lung cancer.
• To propose criteria for selecting promising targeted therapies for adjuvant trials.
• To outline optimal trial designs for the expeditious evaluation of targeted therapies in the adjuvant setting.

Main Methods:

• Review and synthesis of current evidence on adjuvant chemotherapy and targeted therapy in NSCLC.
• Discussion of challenges in adjuvant trial design.
• Proposal of selection criteria for targeted agents and trial designs.

Main Results:

• Survival benefits from adjuvant chemotherapy in early-stage NSCLC are established.
• The need for specific criteria to select targeted therapies for adjuvant use is highlighted.
• The necessity for optimized, expedited trial designs for evaluating these agents is emphasized.

Conclusions:

• The success of adjuvant chemotherapy necessitates a strategic approach to developing and testing targeted therapies in early-stage NSCLC.
• Clear criteria for agent selection and efficient trial designs are crucial for advancing adjuvant targeted therapy.
• Further research into optimal trial methodologies is essential to realize the full potential of targeted agents in this setting.